全球 ADHD（注意力不足过动症）市场：依治疗类型、年龄层、ADHD 亚型、地区、范围和预测

ADHD（注意力不足过动症）市场规模及预测

2024年全球ADHD（注意力不足过动症）市场规模为237.4亿美元，预计2031年将达到389.6亿美元，2024年至2031年复合年增长率为7.05%。ADHD（注意力不足过动症）是一种神经发育障碍，其特征是持续注意力不集中、过动和衝动，干扰日常生活。虽然它主要影响儿童，但它可以持续到成年，影响生活的许多方面，包括学业表现、工作和人际关係。ADHD 管理介入措施包括药物治疗、行为治疗和旨在提高注意力、组织能力和行为的教育支持。

随着数位健康解决方案、个人化医疗的进步以及成人多动症研究的不断增加，过动症治疗的未来看起来充满希望。这些进展预计将提高诊断准确性、治疗效果和患者的整体治疗结果。

ADHD（注意力不足过动症）的全球市场动态

塑造全球 ADHD（注意力不足过动症）市场的关键市场动态

主要市场推动因素

不断提高的认识与支持：

对多动症的认识和宣传不断提高正在推动市场向前发展。例如，2024年8月，National Resource Center on ADHD发起了过动症意识月活动，显着提高了公众和专业人士对过动症的瞭解，从而提高了诊断和治疗的采用率。

诊断技术的进步：

新的诊断工具和技术正在提高过动症诊断的准确性和效率。2024 年 7 月，FDA 批准了一款新的数位 ADHD 诊断应用程序，预计该应用程式将提供更方便、更准确的评估，从而促进市场成长。

扩大治疗选择：

新的和改进的药物和治疗方法是主要驱动力。2024 年 9 月，一家製药公司将宣布推出一种新的 ADHD 治疗方法，可解决注意力不集中和过动症状，预计将扩大治疗选择并推动市场成长。

政府措施和资金：

增加政府对过动症研究和治疗的支持和资助正在推动市场成长。例如，2024 年 6 月，欧盟 (EU) 增加了对过动症研究计画的资助，旨在改善治疗策略和支持系统。

主要课题

偏见和误解：

儘管人们的认识不断提高，但对过动症的耻辱和误解仍然存在。这可能促使不愿寻求诊断和治疗，从而影响为患者提供的护理和支持的整体品质。

昂贵的治疗费用

：对于某些患者来说，过动症的药物、治疗和持续管理可能成本高昂，尤其是在健康保险有限的地区。这种财务障碍可能会限制获得所需的治疗和支援服务。

诊断标准的变化：

ADHD的诊断标准和治疗方法因地区和医疗体系的不同而不同，这可能会导致诊断和治疗的不一致。缺乏标准化可能会影响过动症治疗的可靠性和患者的治疗结果。

获得特殊治疗的机会有限：

专门治疗过动症的医疗保健专业人员供不应求，特别是在农村和服务不足的地区。这种有限的访问可能会阻碍及时的诊断和治疗，影响患者的治疗结果和整体市场的成长。

主要趋势

提高认识和早期诊断：

随着医疗保健专业人员和公众对注意力不足过动症（ADHD）的认识不断加深，诊断可以更早、更准确地进行。教育活动和诊断工具的进步促进了这一趋势，从而提高了检测率和治疗率。

成人多动症诊断增加

随着人们对其盛行率和影响的认识不断提高，以前被忽视的成人多动症正在受到更多关注。诊断标准的改进和对成人多动症症状的更好理解正在增加成人的诊断和个人化治疗选择。

整合数位健康解决方案：

行动应用程式和线上治疗平台等数位健康技术的使用可以改善过动症的管理。这些工具可以改善患者获得护理、即时监测和个人化介入的机会，从而获得更好的结果。

扩大多模式治疗方法：

将药物疗法和行为疗法结合起来以提供更全面的多动症治疗方法的趋势日益明显。这种多模式策略旨在解决疾病的多个方面，从而实现更有效的管理并提高患者的生活品质。

目录

第1章简介

• 市场定义
• 市场细分
• 调查方法

第 2 章执行摘要

• 主要发现
• 市场概况
• 市集亮点

第3章市场概况

• 市场规模和成长潜力
• 市场趋势
• 市场驱动力
• 市场制约因素
• 市场机会
• 波特五力分析

第 4 章 ADHD（注意力不足过动症）市场：依治疗类型

• 药物治疗
• 行为疗法
• 综合治疗

第5章 ADHD（注意力不足过动症）市场：依年龄组

• 孩子
• 成人

第6章 ADHD（注意力不足过动症）市场：依 ADHD 亚型分类

• 注意力不集中主导型
• 过动衝动型
• 复合型

第7章区域分析

• 北美
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东/非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合酋长国

第8章市场动态

• 市场驱动力
• 市场制约因素
• 市场机会
• COVID-19 的市场影响

第9章 竞争格局

• 大公司
• 市场占有率分析

第10章 公司简介

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

第11章市场前景与机遇

• 新兴技术
• 未来市场趋势
• 投资机会

第12章附录

• 缩写表
• 来源和参考文献

Attention-Deficit Hyperactivity Disorder Market Size And Forecast

Global Attention Deficit Hyperactivity Disorder Market size was valued at USD 23.74 Billion in 2024 and is projected to reach USD 38.96 Billion by 2031 , growing at a CAGR of 7.05% from 2024 to 2031. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder marked by persistent patterns of inattention, hyperactivity, and impulsivity that impair daily functioning. It primarily affects children, but it can persist into adulthood, affecting many aspects of life such as academic performance, work, and relationships. ADHD management interventions include medication, behavioral therapy, and educational support tailored to improve focus, organization, and behavior.

The future of ADHD treatment looks promising, thanks to advances in digital health solutions, personalized medicine, and increased research into adult ADHD. These developments are expected to improve diagnostic accuracy, treatment efficacy, and overall patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market Dynamics

The key market dynamics that are shaping the global attention deficit hyperactivity disorder market include:

Key Market Drivers:

Increasing Awareness and Advocacy:

Growing awareness and advocacy efforts for ADHD are propelling the market forward. For instance, in August 2024, the National Resource Center on ADHD launched the ADHD Awareness Month campaign, which significantly increased public and professional understanding of the disorder, resulting in higher diagnosis rates and treatment adoption.

Advances in Diagnostic Technologies:

New diagnostic tools and technologies are improving the accuracy and efficiency of ADHD diagnosis. In July 2024, the FDA approved a new digital ADHD diagnostic app, promising more accessible and precise evaluations and expected to boost market growth.

Expansion of Treatment Options:

New and improved medications and therapies are a major driver. In September 2024, a pharmaceutical company announced the release of a novel ADHD medication that addresses both inattentive and hyperactive symptoms, broadening treatment options and driving market growth.

Government Initiatives and Funding:

Greater government support and funding for ADHD research and treatment are driving market growth. For instance, in June 2024, the European Union increased funding for ADHD research projects, with the goal of improving treatment strategies and support systems, which is expected to drive market growth in Europe and beyond.

Key Challenges:

Stigma and Misconceptions:

Despite growing awareness, stigma and misconceptions about ADHD remain. This can lead to reluctance to seek diagnosis and treatment, affecting the overall quality of care and support provided to patients.

High Cost of Treatment

: ADHD medications, therapies, and ongoing management can be prohibitively expensive for some patients, especially in areas with limited healthcare coverage. This financial barrier may limit access to necessary treatment and support services.

Variability in Diagnostic Criteria:

Differences in ADHD diagnostic criteria and practices between regions and healthcare systems can result in inconsistencies in diagnosis and treatment. This lack of standardization can have an impact on the reliability of ADHD treatment and patient outcomes.

Limited Access to Specialized Care:

There is a shortage of healthcare professionals who specialize in ADHD, especially in rural or underserved areas. This limited access can impede timely diagnosis and treatment, affecting patient outcomes and overall market growth.

Key Trends:

Increasing Awareness and Early Diagnosis:

As healthcare professionals and the general public become more aware of ADHD, diagnoses will be made earlier and more accurately. This trend is aided by educational campaigns and advances in diagnostic tools, which result in higher rates of detection and treatment.

Adult ADHD Diagnosis is Growing:

Adult ADHD, which was previously overlooked, is receiving more attention as awareness of its prevalence and impact grows. Improved diagnostic criteria and a better understanding of adult ADHD symptoms are leading to more diagnoses and personalized treatment options for adults.

Integration of Digital Health Solutions:

The use of digital health technologies, such as mobile apps and online therapy platforms, improves ADHD management. These tools improve patient access to treatment, real-time monitoring, and personalized interventions, resulting in better outcomes.

Expansion of Multimodal Treatment Approaches:

There is an increasing trend of combining medication with behavioral therapies to provide a more comprehensive approach to ADHD treatment. This multimodal strategy aims to address multiple aspects of the disorder, resulting in more effective management and higher patient quality of life.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Attention Deficit Hyperactivity Disorder Market Regional Analysis

Here is a more detailed regional analysis of the global attention deficit hyperactivity disorder market:

North America:

North America dominates the global attention deficit hyperactivity disorder (ADHD) market due to its well-established healthcare infrastructure, high rates of diagnosis, and wide range of treatment options. The region has a comprehensive support system that includes advanced medical facilities, research institutions, and a diverse range of ADHD medications and therapies. This robust healthcare ecosystem ensures that North America remains the leading market for ADHD treatment. For instance, in August 2024, the United States Food and Drug Administration (FDA) approved a new ADHD medication designed specifically for adults, cementing the region's position as a key market due to its strong regulatory framework and significant investment in ADHD research and treatment.

North America is also seeing rapid growth in the ADHD market. This growth is being driven by increased awareness of ADHD, improved diagnostic tools, and expanded access to both medication and behavioral therapies. In July 2024, the National Institute of Mental Health's (NIMH) increased funding for ADHD research are promoting advances in treatment and diagnostics. These efforts are not only improving care quality, but also contributing to the rapid growth of the region's ADHD market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the global attention deficit hyperactivity disorder (ADHD) market, owing to rising awareness, improved diagnostic capabilities, and greater healthcare access. The rise in ADHD diagnosis in countries such as China, India, and Japan is being driven by increased public awareness and the adoption of international diagnostic guidelines. In June 2024, the Indian Ministry of Health launched a national awareness campaign for mental health disorders, including ADHD, which is expected to increase diagnosis rates and treatment accessibility in the region.

Furthermore, the Asia Pacific market is expanding rapidly due to advances in healthcare infrastructure and increased investment in mental health. For instance, in May 2024, the Chinese government announced a significant increase in funding for mental health services, including ADHD treatment, as part of a larger health reform agenda. This investment improves the availability of ADHD treatment options and promotes better diagnostic practices, thereby contributing to the region's rapid market growth.

Global Attention Deficit Hyperactivity Disorder Market: Segmentation Analysis

The Global Attention Deficit Hyperactivity Disorder Market is segmented on the basis of By Treatment Type, By Age Group, By Subtypes of ADHD, and By Geography.

Global Attention Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

Based on Treatment Type, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Medication, Behavioral Therapy, and Combined Therapy. Medication dominates the global ADHD market because it is the primary and most widely used treatment option, providing effective symptom management for a large number of patients. The fastest-growing segment is Combined Therapy, which is driven by a growing recognition of the benefits of combining medication and behavioral therapy for more comprehensive ADHD management and better patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

Based on Age Group, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Children, Adults . Children are the dominant segment in the global ADHD market because the disorder is most commonly diagnosed during childhood, resulting in a greater number of cases and treatment options tailored to this age group. Adults are the fastest-growing segment, thanks to increased awareness of adult ADHD and improved diagnostic practices, which are detecting more cases of ADHD in previously undiagnosed adults.

Global Attention Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

Based on Subtypes of ADHD, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation. The global ADHD market is dominated by Combined Presentation, which includes a wide range of symptoms and is frequently diagnosed due to its comprehensive nature. Predominantly Inattentive Presentation is the fastest-growing segment, with increased awareness of inattentiveness and its consequences, resulting in more diagnoses and treatment options for people who primarily exhibit inattentive symptoms.

Global Attention Deficit Hyperactivity Disorder Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Attention Deficit Hyperactivity Disorder Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America dominates the global Attention Deficit Hyperactivity Disorder (ADHD) market, owing to high diagnosis rates, robust healthcare infrastructure, and significant investments in ADHD treatment and research. Asia Pacific is the fastest-growing region in this market, owing to rising awareness, higher diagnosis rates, and greater access to healthcare services, particularly in emerging economies.

Key Players

• The "Global Attention Deficit Hyperactivity Disorder Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson Services, Inc., Lupin, Novartis AG, Mallinckrodt plc., Purdue Pharma LP, NEOS Therapeutics, Inc., Supernus Pharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Attention Deficit Hyperactivity Disorder Market: Recent Developments
• In September 2024, BrainTech Solutions launched ADHDScan, an innovative digital app for remote ADHD diagnosis. This tool uses AI algorithms to provide accurate assessments, with the goal of improving access to diagnostic services, particularly in underserved areas.
• In July 2024, The World Health Organization (WHO) launched a global ADHD awareness campaign to emphasize the importance of early diagnosis and treatment. This initiative is expected to raise public awareness and lead to increased diagnosis rates worldwide.
• In June 2024, the Behavioral Health Alliance expanded its online therapy platform to include ADHD-specific programs. This expansion makes therapeutic options more accessible to people with ADHD, which helps the market grow.
• In April 2024, MedCore Pharmaceuticals launched a personalized ADHD treatment program tailoring medications and therapies based on genetic tests. This personalized approach aims to improve treatment outcomes and is expected to gain popularity in the market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Attention-Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

5. Attention-Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

6. Attention-Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References